At Usona, we are committed to developing safe and effective treatments for mental health conditions. We are leveraging state-of-the-art scientific and clinical trial methodology to efficiently develop psychedelic drugs and their accompanying supportive therapeutic frameworks for future use within the healthcare system.
We currently have two drug development programs in the clinical stage.
Usona is currently exploring the therapeutic potential of psilocybin for the treatment of major depressive disorder (MDD).LEARN MORE ABOUT PSILOCYBIN
Usona has successfully completed all dosing sessions for our first clinical study evaluating 5-MeO-DMT in healthy volunteers. This represents an important milestone in the clinical development of this promising new treatment.LEARN MORE ABOUT 5-MeO-DMT